Advances in Cancer Immunotherapy™: A Focus on MSI-High and TMB-High Cancers



This Advances in Cancer Immunotherapy™ (ACI) virtual via Zoom program, designed by the Society for Immunotherapy of Cancer (SITC) and presented by leading and local authorities in tumor immunology and cancer immunotherapy, aims to reach practicing clinical oncologists, nurses, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice.

Topics: Biology Deep Dive; TMB Current Data and Approvals; MSI Current Data and Approvals; The Future of MSI & TMB; Patient Education and Engagement in Their Treatment with Immunotherapy; Brief Primer for the Patient and Clinician on Use of NGS for Choosing Immunotherapy.

Learning Objectives:

  • Identify the cancer immunotherapy approaches in use for the treatment of MSI-H/TMB-H cancers
  • Summarize recent updates in cancer immunotherapy for MSI-H/TMB-H cancers
  • Implement cancer immunotherapy for MSI-H/TMB-H cancer into clinical practice appropriately
  • Describe the rationale for the use of cancer immunotherapy in MSI-H/TMB-H cancers
Format: Lectures, faculty debate and panel.

3.75 AMA PRA Category 1 Credits™ - maximum

3.75 ABIM MOC points

3.75 CNE contact hours


November 3, 2021


Virtual Conference